Abound Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$307K Sell
256
-55
-18% -$56.2K 0.06% 74
2026
Q1
$287K Buy
311
+42
+16% +$42.6K 0.07% 70
2025
Q4
$289K Buy
269
+17
+7% +$16.3K 0.07% 68
2025
Q3
$193K Buy
252
+56
+29% +$41.7K 0.05% 87
2025
Q2
$153K Buy
196
+6
+3% +$4.66K 0.04% 96
2025
Q1
$157K Buy
190
+31
+19% +$25.8K 0.05% 83
2024
Q4
$123K Buy
159
+2
+1% +$1.66K 0.04% 92
2024
Q3
$139K Buy
157
+8
+5% +$7.19K 0.05% 81
2024
Q2
$135K Sell
149
-23
-13% -$18.4K 0.05% 72
2024
Q1
$134K Buy
172
+4
+2% +$2.85K 0.05% 73
2023
Q4
$98K Sell
168
-3
-2% -$1.75K 0.04% 89
2023
Q3
$91.9K Sell
171
-2
-1% -$1.03K 0.04% 81
2023
Q2
$81.2K Buy
173
+38
+28% +$15.9K 0.03% 92
2023
Q1
$46.4K Sell
135
-24
-15% -$8.09K 0.02% 129
2022
Q4
$58.3K Buy
159
+37
+30% +$13.1K 0.03% 103
2022
Q3
$39.5K Buy
+122
New +$38.7K 0.02% 131

Other funds holding LLY

Abound Wealth Management's LLY Position: Q2 2026 in Review

Abound Wealth Management reduced its Eli Lilly (LLY) stake by 18% in Q2 2026, selling an estimated $56.2K and leaving 256 shares worth $307K. The position accounts for 0.06% of the portfolio, ranked #74.

Abound Wealth Management first reported a position in LLY in Q3 2022 and has held it in 16 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Abound Wealth Management held 256 shares of Eli Lilly worth $307K as of Q2 2026.
  • Abound Wealth Management sold 55 Eli Lilly shares in Q2 2026, an estimated $56.2K.
  • Eli Lilly made up 0.06% of Abound Wealth Management's portfolio in Q2 2026, its #74 holding.
  • Abound Wealth Management first reported a position in Eli Lilly in Q3 2022 and has held it in 16 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.